April 23, 2018
Marketed therapies are often sufficient in early stages of Parkinson’s disease (PD), but as the disease progresses, they impose a considerable pill burden, progressively lose efficacy, and are…
Amid Substantial Unmet Need, What Clinical Improvements Do Neurologists and Payers Expect of Novel Symptomatic and First-to-Market Disease-Modifying Therapies? Alzheimer’s disease (AD) will pose…